| Autor: |
E, Israel, J M, Drazen, S B, Liggett, H A, Boushey, R M, Cherniack, V M, Chinchilli, D M, Cooper, J V, Fahy, J E, Fish, J G, Ford, M, Kraft, S, Kunselman, S C, Lazarus, R F, Lemanske, R J, Martin, D E, McLean, S P, Peters, E K, Silverman, C A, Sorkness, S J, Szefler, S T, Weiss, C N, Yandava |
| Rok vydání: |
2001 |
| Předmět: |
|
| Zdroj: |
International archives of allergy and immunology. 124(1-3) |
| ISSN: |
1018-2438 |
| Popis: |
Regular use of inhaled beta-adrenergic agonists may have adverse effects in some asthma patients. Polymorphisms of the beta(2)-adrenergic receptor (beta(2)-AR) can affect its regulation; however, results of smaller studies of the effects of such polymorphisms on response to beta-agonist therapy have been inconsistent.We examined the possible effects of polymorphisms at codons 16 (beta(2)-AR-16) and 27 (beta(2)-AR-27) on response to albuterol by genotyping 190 asthmatics who had participated in a trial of regular versus as-needed albuterol use.During the 16-week treatment period, patients homozygous for arginine (Arg/Arg) at beta(2)-AR-16 who used albuterol regularly had a small decline in morning peak expiratory flow (AM PEF). This effect was magnified during a 4-week run-out period, when all patients returned to as-needed albuterol only. By the end of the study, Arg/Arg subjects who had used albuterol regularly had an AM PEF 30.5 +/- 12.1 liters/min lower (p = 0.012) than Arg/Arg patients who had used albuterol as needed only. Subjects homozygous for glycine at beta(2)-AR-16 showed no such decline. Evening PEF also declined in the Arg/Arg regular but not in as-need albuterol users. No significant differences between regular and as-needed treatment were associated with polymorphisms at beta(2)-AR-27.Polymorphisms of the beta(2)-AR may influence airway responses to regular inhaled beta-agonist treatment. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
